Gillian Tan, Columnist

Sanofi Plays Hardball…And Loses

The drugmaker could have avoided a bidding war for Medivation by submitting a higher, friendly offer to begin with.

July 6, 2016 at 6:37 PM UTC

Gillian Tan is a senior reporter covering finance and alternative asset classes including real estate, infrastructure, private equity, private credit, venture capital and sports business. She previously wrote an opinion column for Bloomberg and was a reporter at the Wall Street Journal. She is a qualified chartered accountant.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

When it comes to dealmaking, hardball tactics can backfire -- as Sanofi is finding out.

Late Tuesday, the French drugmaker dropped hostile efforts to acquire oncology specialist Medivation after being granted access to its target's confidential data.